We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Amdocs (DOX) Q2 Earnings Miss Estimates, Revenues Match
Read MoreHide Full Article
Amdocs Limited (DOX - Free Report) reported second-quarter fiscal 2024 results, wherein earnings missed the Zacks Consensus Estimate and revenues matched the same. However, both the top and bottom lines marked a year-over-year improvement.
The company reported second-quarter non-GAAP earnings of $1.56 per share, missing the consensus mark of $1.58. The non-GAAP earnings per share matched the midpoint of management’s guidance of $1.53-$1.59. Quarterly earnings increased 6.1% from the year-ago quarter’s $1.47 per share.
Amdocs reported revenues of $1.25 billion, which came in line with the Zacks Consensus Estimate, as well as matched the midpoint of management’s guidance of $1.23-$1.27 billion. Compared with the year-ago quarter, revenues were up 1.8% on a reported basis and 2% on a constant-currency basis.
Amdocs’ top-line performance was primarily driven by healthy growth in Europe and Rest of the World, offset by a decline in North America.
North America reported revenues of $823.2 million (66% of total revenues), which declined 0.7% year over year. Europe revenues (14.8% of total revenues) of $184.8 million increased 7.6% year over year. Rest of the World revenues (19% of total revenues) grew 6.8% year over year to $237.8 million. Our model estimates for North America, Europe and Rest of the World were pegged at $843.4 million, $181.2 million and $227.4 million, up 1.7%, 5.5% and 2.2%, respectively, year over year.
Managed services revenues rose 0.2% year over year to $720.3 million. The company ended the second quarter of fiscal 2024 with a 12-month backlog of $4.23 billion, up $20 million sequentially and $120 million year over year. Our model estimates for managed services revenues and backlog were pegged at $728.7 million and $4.20 billion, respectively.
The non-GAAP operating income increased 5.4% year over year to $229 million, while the operating margin expanded 60 basis points to 18.4%. The year-over-year improvement in the non-GAAP operating margin was mainly driven by the company’s continuous focus on improving operational excellence and the adoption of automation and artificial intelligence.
Balance Sheet and Cash Flow
Amdocs had cash and short-term investments of $544.4 million as of Mar 31, 2024 compared with $601 million as of Dec 31, 2023.
In the second quarter of fiscal 2024, net cash provided by operating activities was $132.7 million, down from $182.4 million in the previous quarter and $294.5 million in the year-ago period. Free cash flow was $113 million compared with the previous quarter’s $138.6 million and the year-earlier quarter’s $259.4 million.
The company repurchased shares worth $115 million in the second quarter of fiscal 2024.
Amdocs paid out $101 million in dividends and repurchased stocks worth $274 million during the second quarter of fiscal 2024. On May 8, the company’s board approved the next quarterly cash dividend of 47.9 cents. The increased quarterly cash dividend will be first paid on Jul 26 to shareholders of record as of Jun 28, 2024.
FY24 Guidance
For fiscal 2024, the company revised the revenue growth guidance from 1.1-5.1% to 1.6-3.6% on a reported basis. On a constant-currency basis, revenues are now projected to increase in the range of 1.7-3.7%.
For fiscal 2024, the company has lowered the GAAP diluted earnings per share guidance from 13-19.5% to 7.0-13.0%. The non-GAAP earnings per share is estimated to grow in the band of 7.0 -11.0 %.
The fiscal 2024 outlook reflects an expected unfavorable foreign currency impact of approximately 0.1% on a year-over-year basis. For fiscal 2024, the non-GAAP operating margin is expected in a range of 18.1-18.7%, the non-GAAP effective tax rate is anticipated in the band of 13-17% and free cash flow is projected at $700 million.
For the third quarter of fiscal 2024, the company projects revenues between $1.235 billion and $1.275 billion and adjusted earnings in the range of $1.57-$1.63 per share.
Zacks Rank and Stocks to Consider
Currently, Amdocs carries a Zacks Rank #3 (Hold). Shares of the company have lost 4.6% in the past year.
The Zacks Consensus Estimate for NVDA’s 2025 earnings per share has been revised upward by 10 cents to $23.94 in the past 30 days. Shares of NVDA have surged 216.1% in the past year.
The Zacks Consensus Estimate for ANET's 2024 earnings per share has been revised upward by 3 cents to $7.49 in the past 30 days. Shares of ANET have rallied 101.9% in the past year.
The Zacks Consensus Estimate for CRM’s 2024 earnings per share has been revised upward by 3 cents to $9.71 in the past 60 days. Shares of CRM have climbed 39.3% in the past year.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Amdocs (DOX) Q2 Earnings Miss Estimates, Revenues Match
Amdocs Limited (DOX - Free Report) reported second-quarter fiscal 2024 results, wherein earnings missed the Zacks Consensus Estimate and revenues matched the same. However, both the top and bottom lines marked a year-over-year improvement.
The company reported second-quarter non-GAAP earnings of $1.56 per share, missing the consensus mark of $1.58. The non-GAAP earnings per share matched the midpoint of management’s guidance of $1.53-$1.59. Quarterly earnings increased 6.1% from the year-ago quarter’s $1.47 per share.
Amdocs reported revenues of $1.25 billion, which came in line with the Zacks Consensus Estimate, as well as matched the midpoint of management’s guidance of $1.23-$1.27 billion. Compared with the year-ago quarter, revenues were up 1.8% on a reported basis and 2% on a constant-currency basis.
Amdocs Limited Price, Consensus and EPS Surprise
Amdocs Limited price-consensus-eps-surprise-chart | Amdocs Limited Quote
Quarterly Details
Amdocs’ top-line performance was primarily driven by healthy growth in Europe and Rest of the World, offset by a decline in North America.
North America reported revenues of $823.2 million (66% of total revenues), which declined 0.7% year over year. Europe revenues (14.8% of total revenues) of $184.8 million increased 7.6% year over year. Rest of the World revenues (19% of total revenues) grew 6.8% year over year to $237.8 million. Our model estimates for North America, Europe and Rest of the World were pegged at $843.4 million, $181.2 million and $227.4 million, up 1.7%, 5.5% and 2.2%, respectively, year over year.
Managed services revenues rose 0.2% year over year to $720.3 million. The company ended the second quarter of fiscal 2024 with a 12-month backlog of $4.23 billion, up $20 million sequentially and $120 million year over year. Our model estimates for managed services revenues and backlog were pegged at $728.7 million and $4.20 billion, respectively.
The non-GAAP operating income increased 5.4% year over year to $229 million, while the operating margin expanded 60 basis points to 18.4%. The year-over-year improvement in the non-GAAP operating margin was mainly driven by the company’s continuous focus on improving operational excellence and the adoption of automation and artificial intelligence.
Balance Sheet and Cash Flow
Amdocs had cash and short-term investments of $544.4 million as of Mar 31, 2024 compared with $601 million as of Dec 31, 2023.
In the second quarter of fiscal 2024, net cash provided by operating activities was $132.7 million, down from $182.4 million in the previous quarter and $294.5 million in the year-ago period. Free cash flow was $113 million compared with the previous quarter’s $138.6 million and the year-earlier quarter’s $259.4 million.
The company repurchased shares worth $115 million in the second quarter of fiscal 2024.
Amdocs paid out $101 million in dividends and repurchased stocks worth $274 million during the second quarter of fiscal 2024. On May 8, the company’s board approved the next quarterly cash dividend of 47.9 cents. The increased quarterly cash dividend will be first paid on Jul 26 to shareholders of record as of Jun 28, 2024.
FY24 Guidance
For fiscal 2024, the company revised the revenue growth guidance from 1.1-5.1% to 1.6-3.6% on a reported basis. On a constant-currency basis, revenues are now projected to increase in the range of 1.7-3.7%.
For fiscal 2024, the company has lowered the GAAP diluted earnings per share guidance from 13-19.5% to 7.0-13.0%. The non-GAAP earnings per share is estimated to grow in the band of 7.0 -11.0 %.
The fiscal 2024 outlook reflects an expected unfavorable foreign currency impact of approximately 0.1% on a year-over-year basis. For fiscal 2024, the non-GAAP operating margin is expected in a range of 18.1-18.7%, the non-GAAP effective tax rate is anticipated in the band of 13-17% and free cash flow is projected at $700 million.
For the third quarter of fiscal 2024, the company projects revenues between $1.235 billion and $1.275 billion and adjusted earnings in the range of $1.57-$1.63 per share.
Zacks Rank and Stocks to Consider
Currently, Amdocs carries a Zacks Rank #3 (Hold). Shares of the company have lost 4.6% in the past year.
Some better-ranked stocks from the broader technology sector are NVIDIA (NVDA - Free Report) , Arista Networks (ANET - Free Report) and Salesforce (CRM - Free Report) , each carrying a Zacks Rank #2 (Buy) at present. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
The Zacks Consensus Estimate for NVDA’s 2025 earnings per share has been revised upward by 10 cents to $23.94 in the past 30 days. Shares of NVDA have surged 216.1% in the past year.
The Zacks Consensus Estimate for ANET's 2024 earnings per share has been revised upward by 3 cents to $7.49 in the past 30 days. Shares of ANET have rallied 101.9% in the past year.
The Zacks Consensus Estimate for CRM’s 2024 earnings per share has been revised upward by 3 cents to $9.71 in the past 60 days. Shares of CRM have climbed 39.3% in the past year.